Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in progressive advanced/metastatic unresectable well-differentiated pancreatic neuroendocrine tumors
2011-004363-74Phase 4Completed
- Sponsor
- Pfizer
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sunitinib in islet cell tumor, sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Dec 2011; status: completed.
02
Drugs
sunitinib
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on 2011-004363-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004363-74.